BAY2701250 IV + Placebo IV + BAY2701250 SC + Placebo SC
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension Due to Left Heart Disease
Conditions
Pulmonary Hypertension Due to Left Heart Disease
Trial Timeline
Sep 15, 2023 → May 20, 2025
NCT ID
NCT06048120About BAY2701250 IV + Placebo IV + BAY2701250 SC + Placebo SC
BAY2701250 IV + Placebo IV + BAY2701250 SC + Placebo SC is a phase 1 stage product being developed by Bayer for Pulmonary Hypertension Due to Left Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06048120. Target conditions include Pulmonary Hypertension Due to Left Heart Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06048120 | Phase 1 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension Due to Left Heart Disease